[The effect of calcitriol on renal anemia in patients under chronic hemodialysis].
The authors reached the suppression of serum intact parathormone (iPTH) by calcitriol therapy in chronic hemodialyzed patients with secondary hyperparathyroidism. Parallel with the depression of iPTH levels it was enough a lower doses of recombinant human erythropoietin (Rh-EPO) to maintain the target hematocrit, while on two patients non-treated with Rh-EPO they founded an improvement in moderate anemia. Their data confirm that the calcitriol is an effective drug in the treatment of secondary hyperparathyroidism. The results speak in favour that in the improvement of renal anemia on regular hemodialysis patients play an important role the suppression of serum iPTH levels too.
Abou-Khalil
N
N
Semmelweis Orvostudományi Egyetem, Budapest, Urológiai Klinika.
Makó
J
J
D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D002117:Calcitriol / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage; D006400:Hematocrit; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D010281:Parathyroid Hormone / Q000097:blood; D011994:Recombinant Proteins; D006435:Renal Dialysis
D010281:Parathyroid Hormone; D011994:Recombinant Proteins; D004921:Erythropoietin; D002117:Calcitriol